



Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,
P.O. Tandaheeri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542

Email: genomicvalley@gmail.com; Visit: <http://www.genomicvalley.com>

Dated: 30th May, 2018

To,
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)
Sub: Compliance under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Filing of Audited Financial Results for the Quarter and Year ended 31st March, 2018

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2018 duly approved by the Board of Directors of the Company, at its meeting held today, the 30th day of May, 2018. The Meeting of Board of Directors of the Company commenced at 11:45 A.M. and concluded at 04:30 P.M.

We are also enclosing a copy of the Auditor's Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further we are enclosing a copy of Declaration given by Managing Director and Chief Financial Officer pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular no. CIR/ CFD/ CMD/56/2016 dated May, 27, 2016.

You are requested to kindly take the same into your records.

Thanking you.

Yours faithfully,

For and on behalf of
Genomic Valley Biotech Limited

Hitesh



Hitesh Kumar
Company Secretary & Compliance officer

Encl: A/A



A.K. Khattar & Associates
Chartered Accountants

112-A, Ground Floor, DDA Complex,
Jhandewalan Extn-1, New Delhi - 110055
Ph: 011-43570260

INDEPENDENT AUDITOR'S REPORT

To,

The Board of Directors of
Genomic Valley Biotech Limited
4 K.M. Stone, Beri Chharra Road,
Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh,
Distt-Jhajjar, Haryana-124507

Subject: Independent Auditor's Report on the Audited Financial Results for the Quarter and Year ended

Genomic Valley Biotech Limited ('the Company') for the quarter and year ended March 31, 2018 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone Ind AS financial Statement which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statements based on our audit of such standalone financial Statements.

3. We conducted our audit in accordance with the Standard on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatement.

An audit involves performing procedures to obtain audited evidence about the amount and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used in the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanation given to us, the Statement:
 - (i) is presented in accordance with the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016; and
 - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and the other accounting principles generally accepted in India of the Net Profit/Loss and Total Comprehensive Income/Loss and other financial information of the Company for the Year ended March 31, 2018.



5. The Statement includes the results for the Quarter ended March 31, 2018 being the balancing figure between audited figures in respect of the full financial year and the audited year to date figures up to the third quarter of the current financial year.



For and on behalf of
A.K. KHATTAR & ASSOCIATES
Chartered Accountants

(A.K. KHATTAR)
(Prop.)
(Membership No.-084960)

Place: Delhi
Date: May 30, 2018

Regd. Off: 4 F
TEHSIL-B

Statement of Standalone Aud

TECH LIMITED
RA ROAD, P.O. T
AJJA
PLC
HARYANA
124507
133029

the quarter and year ended March 31, 2018


Sr	Particular	For the quarter ended			For the year ended		
		31-Dec-17	31-Mar-17	31-Mar-17	31-Mar-18	31-Mar-17	31-Mar-17
		Un-Audited	Audited	Audited	Audited	Audited	Audited
I	Revenue From Operations						
II	Other Income						
III	Total Revenue (I+II)						
IV	Expenses						
	Cost of materials consumed						
	Purchases of Stock-in-trade						
	Changes in inventory						
	Trade						
	% of finished goods work-in-progress						
	Employee benefits expense						
	Financial costs						
	Depreciation and amortization expense						
	Other expenses						
	Total Expenses (IV)						
	Profit / (Loss) before exceptional item and tax (III-IV)						
V	Exceptional item						
VI	Profit/loss before Tax (V-VI)						
VII	Tax expenses						
VIII	(1) Current Tax						
	(2) Deferred Tax						
IX	Profit/ (Loss) for the period from continuing operations (VI)						
X	Profit/ (Loss) from discontinued operations						
XI	Tax expense of discontinued operations						
XII	Profit/ (Loss) from discontinued operations (after tax) (X-XI)						

In Rs.



Handwritten signature

XIII	Profit/Loss for the period (IX+XII)	438,105	-182,266	261,309	340,905	-685,732
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	438,105	-182,266	261,309	340,905	-685,732
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	
XVII	Earning Per Equity Share (for continuing operation):					
	1) Basic	0.14	-0.06	0.09	0.11	-0.22
	2) Diluted	0.14	-0.06	0.09	0.11	-0.22
XVIII	Earning Per Equity Share (for discontinued operation):					
	1) Basic	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):					
	1) Basic	0.14	-0.06	0.09	0.11	-0.22
	2) Diluted	0.14	-0.06	0.09	0.11	-0.22




Statement of Asset and Liabilities

Particulars	As at	
	31/03/2018	31/03/2017
	Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	41,205,043	36,331,961
Capital work in progress	3,767,076	-
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	20,600,000	21,500,000
Security Deposits	287,788	260,000
Other financial assets	-	-
Deferred tax assets (Net)	-	117,620
Other non current assets	-	-
Total Non-Current Assets	65,859,908	58,209,581
Current Assets		
Inventories	331,798	706,763
Financial Assets:	-	-
Investments	-	-
Trade Receivables	223,362	-
Cash and Cash equivalents	33,300	243,400
Other Balances with banks	89,247	228,388
Loans	-	-
Other financial assets	-	-
Other Current assets	204,961	886,730
Total Current Assets	882,668	2,065,281
Total Assets	66,742,576	60,274,862
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	30,545,000	30,545,000
Other Equity	14,740,266	14,399,361
Total Equity	45,285,266	44,944,361
Non Current Liabilities		
Financial liabilities		
Borrowings	7,500,000	7,500,000
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	127,351	-
Provisions	-	-
Other Non Current liabilities	-	-
Total Non Current Liabilities	7,627,351	7,500,000
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	75,000	100,000
Other Financials liabilities	-	-
Provisions	261,680	154,000
Other Current liabilities	13,493,279	7,576,501
Total Current Liabilities	13,829,959	7,830,501
TOTAL EQUITY AND LIABILITIES	66,742,576	60,274,862

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on May 30, 2018 and the Statutory Auditors of the company have audited these financials results.

- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment.



[Redacted signature]

- 5 There is change in accounting estimate, life of the Green House(Temporary Structure) from 3 to 4 Years and the effect of it has been reflected in the carrying value of asset as at 31.03.2018

Particulars	Depreciation as per New Life	Depreciation as per Old Life	Difference
Green house	348855.2	465140.27	116285.07

Due to improved technology in management it has become a very high class structure with a long life span. During the period under consideration...

Place : Delhi
Dated : 30/05/2018



For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited


Yogesh Agrawal
Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063



Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507

CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542

Email: genomicvalley@gmail.com; Visit: <http://www.genomicvalley.com>

Declaration of Un-Modified Audit Report pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We, Yogesh Agrawal, Managing Director and Lalit Shah, Chief Financial Officer of Genomic Valley Biotech Limited having its Registered Office at 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman, P.O. Tandaheri, Tehsil-Bahadurgarh, Distt- Jhajjar, Haryana-124507, hereby declare that A. K Khattar & Associates, Chartered Accountants (M. No. 084960), Statutory Auditors of the Company, has issued an Auditor Report with Un-Modified opinion on Audited Financial Results of the Company (Standalone) for the quarter and year ended 31st March, 2018.

This declaration is given pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

For Genomic Valley Biotech Limited

Yogesh Agrawal
Managing Director
DIN No. 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi-110063



Lalit Shah
Chief Financial Officer
PAN No. BCHPS9526B
Address: Flat No. 303, Pacific Tower,
Omaxe City, Rohtak Road,
Bahadurgarh-124507

Dated: 30.05.2018

Place: Delhi